# Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

> **NCT02204371** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 7 (actual)

## Conditions studied

- Telangiectasia, Hereditary Hemorrhagic

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02204371
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-25
- **Primary completion:** 2016-02-10
- **Final completion:** 2016-02-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was terminated as the asset was sold to another company who decided not to pursue this indication with this drug.
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204371, "Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02204371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*